Literature DB >> 10485711

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling.

J A Romashkova1, S S Makarov.   

Abstract

The mechanisms of cell proliferation and transformation are intrinsically linked to the process of apoptosis: the default of proliferating cells is to die unless specific survival signals are provided. Platelet-derived growth factor (PDGF) is a principal survival factor that inhibits apoptosis and promotes proliferation, but the mechanisms mediating its anti-apoptotic properties are not completely understood. Here we show that the transcription factor NF-kappaB is important in PDGF signalling. NF-kappaB transmits two signals: one is required for the induction of proto-oncogene c-myc and proliferation, and the second, an anti-apoptotic signal, counterbalances c-Myc cytotoxicity. We have traced a putative pathway whereby PDGF activates NF-kappaB through Ras and phospatidylinositol-3-kinase (PI(3)K) to the PKB/Akt protein kinase and the IkappaB kinase (IKK); NF-kappaB thus appears to be a target of the anti-apoptotic Ras/PI(3)K/Akt pathway. We show that, upon PDGF stimulation, Akt transiently associates in vivo with IKK and induces IKK activation. These findings establish a role for NF-kappaB in growth factor signalling and define an anti-apoptotic Ras/PI(3)K/Akt/IKK/NF-kappaB pathway, thus linking anti-apoptotic signalling with transcription machinery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485711     DOI: 10.1038/43474

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  452 in total

Review 1.  NF-kappaB: a key role in inflammatory diseases.

Authors:  P P Tak; G S Firestein
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Insulin-like growth factor-mediated muscle cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21.

Authors:  M A Lawlor; P Rotwein
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt.

Authors:  F Scholle; K M Bendt; N Raab-Traub
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis.

Authors:  M P Scheid; J R Woodgett
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-01       Impact factor: 2.673

Review 5.  Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases.

Authors:  Adam P Curnock; Marisa K Logan; Stephen G Ward
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

6.  Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes.

Authors:  Hajir Dadgostar; Brian Zarnegar; Alexander Hoffmann; Xiao-Feng Qin; Uyen Truong; Govinda Rao; David Baltimore; Genhong Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

7.  Cooperative control of Akt phosphorylation, bcl-2 expression, and apoptosis by cytoskeletal microfilaments and microtubules in capillary endothelial cells.

Authors:  D A Flusberg; Y Numaguchi; D E Ingber
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

Review 8.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

Review 9.  Hostile takeovers: viral appropriation of the NF-kappaB pathway.

Authors:  J Hiscott; H Kwon; P Génin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

10.  IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf.

Authors:  Chris Albanese; Kongming Wu; Mark D'Amico; Christy Jarrett; David Joyce; Julian Hughes; James Hulit; Toshiyuki Sakamaki; Maofu Fu; Avri Ben-Ze'ev; Jacqueline F Bromberg; Carmela Lamberti; Udit Verma; Richard B Gaynor; Stephen W Byers; Richard G Pestell
Journal:  Mol Biol Cell       Date:  2003-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.